Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million Phase Four unveils game changing engine for LEO Constellations
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.

 

Cookie Policy Privacy Policy